Table 5 Parasite prevalence and access to anti-malaria treatment
| Â | Malaria parasite prevalence | Access to anti-malaria treatment Children under 5Â years | ||||
|---|---|---|---|---|---|---|
General population % (95 % CI) | Children under 5 years % (95 % CI) | Women aged 15–49 years  % (95 % CI) | Had fever last 2 weeks % (95 % CI) | Sought treatment/advice % (95 % CI) | AS-AQ same day/next day % (95 % CI) | |
Residency | Â | Â | Â | Â | Â | Â |
 Rural | 1.3 % (1.0–1.6) | 1.5 % (1.0–2.2) | 1.9 % (1.4–2.5) | 20 % (14–26) | 56 % (52–67) | 2.6 % (1.1–6.4) |
 Urban | 0.5 % (0.3–0.8) | 0.9 % (0.4–2.3) | 0.1 % (0.02–0.64) | 19 % (10–31) | 65 % (52–77) | 0 |
Zoba | Â | Â | Â | Â | Â | Â |
 Anseba | 0 | 0 | 0.2 % (0.1–0.8) | 11 % (4–24) | 60 % (46–75) | 0 |
 Debub | 0.8 % (0.5–1.2) | 1.5 % (0.8–3.0) | 2.1 % (1.3–3.3) | 21 % (13–33) | 58 % (46–70) | 1.7 % (0.3–8.8) |
 Gash Barka | 2.6 % (2.1–3.2) | 2.5 % (1.5–4.1) | 1.9 % (1.5–3.8) | 27 % (18–38) | 63 % (52–73) | 3.2 % (1.0–9.8) |
 Semenawi Keih Bahri | 0.1 % (0.02–0.31) | 0.2 % (0.03–1.38) | 0.1 % (0.01–0.72) | 11 % (4–25) | 64 % (46–77) | 0 |
 Total | 1.1 % (1.0–1.3) | 1.4 % (1.0–2.0) | 1.4 % (1.0–1.9) | 19 % (15–26) | 61 % (54–67) | 2 % (0.8–4.9) |